Pharm-Bio Serv (PBSV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Sep 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBSV SEC filings page.
Pharm-Bio Serv Inc (PBSV) reported $9.5M in revenue over the twelve months to Jul 31, 2026, up 3.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pharma-Bio Serv is shrinking its revenue base, but lower delivery costs are narrowing losses while shareholder distributions keep reducing its capital cushion.
The FY2025 recovery is concentrated below the sales line: gross margin reached32.3% , but SG&A consumed39.4% of revenue, leaving an operating loss of$638K . The net loss was only$100K , yet operating cash flow remained negative at-$215K , so reported earnings looked closer to break-even than the underlying operations did.
Revenue fell
The balance sheet is lightly burdened, with liabilities at
Financial Health Signals
Pharm-Bio Serv Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pharm-Bio Serv Inc scores 6.72, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $11.9M against total liabilities of $1.7M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Pharm-Bio Serv Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Pharm-Bio Serv Inc reported a net loss of $100K while operations used $215K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Pharm-Bio Serv Inc generated $2.3M in revenue in Q3 2026. This represents an increase of 19.0% from the same quarter a year earlier. Against the prior quarter it is down 13.6%.
Pharm-Bio Serv Inc's EBITDA was -$58K in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 136.7%.
Pharm-Bio Serv Inc reported a net loss of $14K in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 106.1%.
Cash & Balance Sheet
Pharm-Bio Serv Inc generated $60K in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 74.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Pharm-Bio Serv Inc held $1.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Pharm-Bio Serv Inc's gross margin was 29.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.8 percentage points.
Pharm-Bio Serv Inc's operating margin was -3.1% in Q3 2026, reflecting core business profitability. This is up 12.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.4 percentage points.
Pharm-Bio Serv Inc's net profit margin was -0.6% in Q3 2026, showing the share of revenue converted to profit. This is up 9.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.2 percentage points.
Pharm-Bio Serv Inc's quarterly ROE was -0.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.
Capital Allocation
Pharm-Bio Serv Inc repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Pharm-Bio Serv Inc invested $1K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 31.7% from the same quarter a year earlier. Against the prior quarter it is down 40.1%.
Not reported for Q3 2026.
PBSV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M+19.0% | $2.7M+11.8% | $2.3M-7.1% | $2.1M-7.9% | $2.0M-18.8% | $2.4M+1.7% | $2.5M+3.8% | $2.3M-35.2% |
| Cost of Revenue | $1.6M+18.4% | $1.8M+12.7% | $1.6M-7.7% | $1.4M-12.8% | $1.4M-22.1% | $1.6M-9.1% | $1.7M-7.7% | $1.6M-39.8% |
| Gross Profit | $692K+20.5% | $902K+10.2% | $722K-6.0% | $749K+3.1% | $574K-9.6% | $819K+32.4% | $768K+43.4% | $727K-21.9% |
| SG&A Expenses | $764K-14.0% | $757K-17.4% | $817K-5.0% | $882K+0.2% | $888K-12.7% | $917K-1.6% | $860K-11.7% | $881K-10.3% |
| Operating Income | -$72Kn/m | $145Kn/m | -$95Kn/m | -$133Kn/m | -$314Kn/m | -$98Kn/m | -$92Kn/m | -$154Kn/m |
| EBITDA | -$58Kn/m | $158Kn/m | -$80Kn/m | -$117Kn/m | -$298Kn/m | -$79Kn/m | -$83Kn/m | -$148Kn/m |
| Income Tax | $3Kn/m | $6K+15.5% | $4K+225.6% | $4Kn/m | -$5K-125.1% | $6K-74.0% | $1K-91.4% | -$31Kn/m |
| Net Income | -$14Kn/m | $233K+144.3% | $33K+285.0% | -$102-100.6% | -$204Kn/m | $95Kn/m | $9Kn/m | $16Kn/m |
| EPS (Diluted) | $0.00 | $0.01+150.0% | $0.00n/m | -$0.01n/m | -$0.01-164.3% | $0.00n/m | $0.00n/m | -$0.07 |
| Diluted Shares (Avg) | 23M | 23M-0.1% | 23M-0.2% | N/A | 23M-0.1% | 23M-0.1% | 23M-0.1% | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense, EPS (Basic).
PBSV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.4M-15.8% | $11.5M-17.3% | $13.5M-15.7% | $13.7M-16.2% | $13.6M-16.7% | $13.9M-17.9% | $16.1M-16.4% | $16.3M-18.1% |
| Current Assets | $11.2M-14.6% | $11.3M-15.9% | $13.3M-14.2% | $13.4M-14.7% | $13.2M-17.4% | $13.4M-18.7% | $15.5M-17.3% | $15.7M-19.1% |
| Cash & Equivalents | $1.5M-61.6% | $1.8M-14.4% | $5.8M-21.1% | $3.4M-50.1% | $4.0M-39.3% | $2.1M-40.4% | $7.3M+13.9% | $6.8M-35.2% |
| Short-Term Investments | $7.1M+4.3% | $6.7M-19.6% | $4.8M-6.5% | $7.5M+25.0% | $6.8M+6.7% | $8.3M-16.5% | $5.1M-45.9% | $6.0M+31.9% |
| Accounts Receivable | $2.4M+20.1% | $2.7M+1.5% | $2.7M-1.0% | $2.4M-6.0% | $2.0M-22.5% | $2.7M+2.6% | $2.7M+11.4% | $2.5M-36.3% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $995K-40.0% | $1.0M-41.3% | $3.3M-18.9% | $1.7M-32.5% | $1.7M-37.0% | $1.8M-40.1% | $4.1M-19.6% | $2.6M-31.7% |
| Current Liabilities | $995K-40.0% | $1.0M-41.3% | $3.3M-3.2% | $1.7M-7.9% | $1.7M-12.7% | $1.8M-19.0% | $3.4M-7.0% | $1.9M-12.4% |
| Non-Current Liabilities | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $661K-52.7% | $690K-57.5% |
| Total Equity | $10.4M-12.4% | $10.5M-13.8% | $10.2M-14.6% | $11.9M-13.1% | $11.9M-12.9% | $12.1M-13.1% | $12.0M-15.3% | $13.7M-15.0% |
| Retained Earnings | $9.1M-13.9% | $9.1M-15.4% | $8.8M-16.9% | $10.5M-14.7% | $10.5M-14.6% | $10.7M-15.1% | $10.6M-17.2% | $12.4M-16.8% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
PBSV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $61K-74.3% | -$365Kn/m | -$390Kn/m | $280K+256.6% | $237Kn/m | -$302Kn/m | -$429K-159.2% | $78K-74.6% |
| Depreciation & Amortization | $14K-13.1% | $14K-27.7% | $15K+56.8% | $16K+166.8% | $16K+243.1% | $19K+242.5% | $9K+29.5% | $6K-19.8% |
| Stock-Based Compensation | $9K-13.8% | $9K-13.8% | $9K-19.3% | N/A | $10K-32.4% | $10K-32.4% | $11K-27.8% | N/A |
| Capital Expenditures | $1K-31.7% | $2K-45.5% | $2Kn/m | $350-99.8% | $2K+6.7% | $4Kn/m | $0-100.0% | $157K |
| Free Cash Flow | $60K-74.6% | -$368Kn/m | -$393Kn/m | $279Kn/m | $234Kn/m | -$306Kn/m | -$429K-159.2% | -$79K |
| Investing Cash Flow | -$326K-120.0% | -$1.9Mn/m | $2.8M+179.9% | -$857K-599.4% | $1.6M-55.9% | -$3.2Mn/m | $988Kn/m | $172K-97.7% |
| Financing Cash Flow | $0n/m | -$1.7Mn/m | -$2Kn/m | -$9Kn/m | -$5Kn/m | -$1.7Mn/m | $0n/m | $0n/m |
| Dividends Paid | $0n/m | $1.7M-0.1% | N/A | $0n/m | $0n/m | $1.7M-0.1% | N/A | $0n/m |
| Share Buybacks | $0-100.0% | $709-95.9% | $2Kn/m | $9Kn/m | $5K+186.4% | $17K+642.0% | $0-100.0% | $0-100.0% |
PBSV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.6%+0.4pp | 33.4%-0.5pp | 31.5%+0.4pp | 34.8%+3.7pp | 29.3%+3.0pp | 33.9%+7.9pp | 31.1%+8.6pp | 31.1%+5.3pp |
| Operating Margin | -3.1%+12.9pp | 5.3%+9.4pp | -4.1%-0.4pp | -6.2%+0.4pp | -16.0%-0.2pp | -4.1%+9.1pp | -3.7%+14.7pp | -6.6%-5.2pp |
| Net Margin | -0.6%+9.8pp | 8.6%+4.7pp | 1.4%+1.1pp | 0.0%-0.7pp | -10.4%+2.4pp | 4.0%+12.9pp | 0.4%+11.7pp | 0.7%+2.0pp |
| Return on Equity | -0.1%+1.6pp | 2.2%+1.4pp | 0.3%+0.3pp | 0.0%-0.1pp | -1.7%+0.5pp | 0.8%+2.3pp | 0.1%+2.0pp | 0.1%+0.4pp |
| Return on Assets | -0.1%+1.4pp | 2.0%+1.3pp | 0.2%+0.2pp | 0.0%-0.1pp | -1.5%+0.4pp | 0.7%+1.9pp | 0.1%+1.5pp | 0.1%+0.3pp |
| Current Ratio | 11.30+3.4x | 10.80+3.3x | 4.03-0.5x | 7.70-0.6x | 7.93-0.5x | 7.540.0x | 4.54-0.6x | 8.32-0.7x |
| Liabilities-to-Equity | 0.100.0x | 0.100.0x | 0.320.0x | 0.150.0x | 0.14-0.1x | 0.15-0.1x | 0.340.0x | 0.190.0x |
| Asset Turnover | 0.20+0.1x | 0.24+0.1x | 0.170.0x | 0.160.0x | 0.140.0x | 0.170.0x | 0.150.0x | 0.140.0x |
| FCF Margin | 2.5%-9.4pp | -13.6%-1.0pp | -17.1%+0.3pp | 13.0%+16.4pp | 11.9%+39.7pp | -12.7%+16.8pp | -17.4%-47.9pp | -3.4% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Pharm-Bio Serv Inc PBSV | FY2025 | $9.0M | -$100K | -1.1% | $11.9M | — |
| CAREVIEW COMMUNS INC CRVW | FY2025 | $9.0M | -$3.2M | -35.5% | $19.6M | — |
Where Pharm-Bio Serv Inc Ranks
Frequently Asked Questions
Pharm-Bio Serv Inc (PBSV) reported $9.0M in total revenue for fiscal year 2025. This represents a -5.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Pharm-Bio Serv Inc (PBSV) revenue declined by 5.3% year-over-year, from $9.5M to $9.0M in fiscal year 2025.
Yes, Pharm-Bio Serv Inc (PBSV) reported a net income of $252K over the trailing 12 months to July 31, 2026. In fiscal year 2025 it reported a net loss of $100K, with a net profit margin of -1.1%.
Pharm-Bio Serv Inc (PBSV) had EBITDA of -$578K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Pharm-Bio Serv Inc (PBSV) had a gross margin of 32.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Pharm-Bio Serv Inc (PBSV) had an operating margin of -7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Pharm-Bio Serv Inc (PBSV) had a net profit margin of -1.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Pharm-Bio Serv Inc (PBSV) has a return on equity of -0.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Pharm-Bio Serv Inc (PBSV) recorded an outflow of $222K in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Pharm-Bio Serv Inc (PBSV) recorded an outflow of $215K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Pharm-Bio Serv Inc (PBSV) had $13.7M in total assets as of fiscal year 2025, including both current and long-term assets.
Pharm-Bio Serv Inc (PBSV) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Pharm-Bio Serv Inc (PBSV) had a current ratio of 7.70 as of fiscal year 2025, which is generally considered healthy.
Pharm-Bio Serv Inc (PBSV) had a liabilities-to-equity ratio of 0.15 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Pharm-Bio Serv Inc (PBSV) had a return on assets of -0.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Pharm-Bio Serv Inc (PBSV) trades at 47.3x earnings, its market capitalization divided by $252K net income, trailing 12 months to July 31, 2026. The market capitalization is $11.9M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Pharm-Bio Serv Inc (PBSV) trades at 1.3x sales, its market capitalization divided by $9.5M revenue, trailing 12 months to July 31, 2026. The market capitalization is $11.9M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Pharm-Bio Serv Inc (PBSV) has an Altman Z-Score of 6.72, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Pharm-Bio Serv Inc (PBSV) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Pharm-Bio Serv Inc (PBSV) reported a net loss of $100K while operations used $215K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.